Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Payback Time For Lilly? Erbitux Follow-on Succeeds In Squamous Lung Cancer Trial

This article was originally published in The Pink Sheet Daily

Executive Summary

Lilly’s necitumumab – gained through the company’s ImClone acquisition – demonstrates an overall survival benefit in the SQUIRE study against first-line metastatic squamous NSCLC. Pleasantly surprised by the outcome, some analysts start to expect blockbuster sales.

Advertisement

Related Content

Lilly's Necitumumab: FDA Panel To Weigh Modest Survival Benefit Against Thromboembolic Risks
Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
Lilly Drug Shows Survival Benefit In NSCLC, Raising Its Prospects
Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
Lilly’s Ramucirumab Fails In Breast Cancer Trial, Clears Second Gastric Cancer Study
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Ramucirumab Becomes First Lilly ImClone Compound To Enjoy Phase III Success
Blood Clot Risk Causes Lilly, Bristol To Halt Enrollment In Erbitux Follow-On Trial
Lilly Snatches ImClone Away From Bristol
FLEX Shows Erbitux’s Strength With Survival Benefit In NSCLC

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS076096

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel